Aino Health AB (publ): Interim report january-september 2023
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.
100,000 implemented licenses. Improved net sales, profitability and cashflow
January – September 2023
- Net sales were KSEK 17,605 (15,248)
- Profit/loss after financial items was KSEK -6,812 (-10,522)
- Earnings per share were SEK -0.2 (-0.3)
July – September 2023
- Net sales were KSEK 5,633 (4,839)
- Profit/loss after financial items was KSEK -1,215 (-3,127)
- Earnings per share were SEK 0 (-0.1)
It is with great confidence that I want to start by saying that we have successfully implemented 100,000 licenses. It confirms our trust-building work and the power of our platform. We continue to demonstrate the potential and power that our digital solutions carry with them. I would also like to highlight the issue we carried out during this quarter. This strategic measure reduces the company’s debts and strengthens our liquidity. Net sales for this quarter has increased. This increase reflects our commitment, dedication and the hard work put in by the entire team behind Aino. Together with the improved cash flow from current operations, we see clear signs of a positive and sustainable economic development. We live in a time when Human Capital Management is becoming increasingly central. The global business community not only expects innovative digital solutions, but now sees them as a necessity. It is about transparency in the business, open dialogue between employees and management, and a culture where every individual feels valued. With our SaaS solution, we continue to lead the way in meeting these expectations and needs.
The information contained herein is such as shall be made public by Aino Health AB (publ), in accordance with the EU Market Abuse Regulation. This information was made public, through the agency of Jyrki Eklund, CEO and President of Aino Health AB, at 08.30 AM CET on november 10, 2023.
For more information
Jyrki Eklund
CEO Aino Health
Phone: +358 40 042 4221
jyrki.eklund@ainohealth.com
Certified adviser
Erik Penser Bank
For more information see: https://investors.ainohealth.com/certified-adviser/
About Aino Health (publ)
Aino Health is the leading provider of Software as a Service solutions in Corporate Health Management.
The company’s complete system of SaaS platforms and services reduces sick leave, lowers related costs and improves business outcomes through increased productivity and employee engagement by making health, well-being and safety an integral part of daily work. For more information visit ainohealth.com.
Link to the report
https://investors.ainohealth.com/rapporter-och-dokument/
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Hexagon Purus awarded purchase order by Ford Trucks to deliver a hydrogen fuel storage system for their prototype heavy-duty truck7.12.2023 08:07:00 CET | Press release
(Oslo, 7 December 2023) Hexagon Purus, a world leading supplier of zero-emission infrastructure and mobility solutions, has been awarded a purchase order by Ford Trucks to deliver a complete hydrogen fuel storage system for development of a Fuel Cell Electric-Powered Vehicle (FCEV) F-MAX as part of the Horizon Europe project ZEFES (Zero Emission Freight EcoSystem), a zero-emission logistics deployment project in which Ford Trucks participates with the vision of pioneering future transportation solutions. As a partner in project ZEFES, a pan-European project specifically targeting decarbonization of long-haul heavy-duty trucking in Europe, Ford Trucks will develop and deliver a fuel cell electric heavy-duty prototype F-MAX truck that will operate as part of a larger fleet of zero-emission trucks collecting data from real-world operations. The F-MAX FCEV will be Ford Trucks’ first fuel cell-powered vehicle, developed and manufactured in Turkey, and will begin European Ten-T corridor demo
AB Akola Group: notification on disposal of voting rights7.12.2023 08:04:58 CET | Press release
AB Akola Group (former AB Linas Agro Group), ISIN code LT0000128092 (hereinafter - the Company), received notification from UAB „SB Asset Management“ on the disposal of voting rights due to the increase in the authorized capital of the Company (enclosed). Additional information: Mažvydas Šileika, CFO of AB Akola Group Mob. +370 619 19 403 E-mail m.sileika@akolagroup.lt Attachment Notification-of-disposal-of-block-of-shares LNA 2023 12 06-s1206
Dividend Declaration7.12.2023 08:00:00 CET | Press release
Volta Finance Limited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 7 December 2023 Volta Finance Limited ("the Company") hereby announces that it has declared a quarterly interim dividend of €0.135 per share payable on 25 January 2024 amounting to approximately €4.94 million, approximately equating to an annualised 8.25% of net asset value. The ex-dividend date is 21 December 2023 with a record date of 22 December 2023. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Computershare either electronically via CREST or by using the Currency Election Form which has
Tag Systems and Fingerprint Cards AB (Fingerprints™) to bring biometric card to market7.12.2023 08:00:00 CET | Press release
Global card manufacturer Tag Systems (part of AUSTRIACARD Holdings AG) has achieved Mastercard certification for its biometric card based on Fingerprint Cards’ sensor and STMicroelectronics STPay-Topaz-Bio solution. Banks and fintechs can now issue Mastercard-branded biometric payment cards to enhance convenience and security for cardholders. Roger Carrico, Vice President, Head of Sales & Business development, Payment & Access at Fingerprints comments: “In Tag Systems we have a partner that likes to lead the way with high-end payment services. Banks and fintechs can take advantage of the opportunity to differentiate, retain and acquire customers and drive revenues.” Jon Neeraas, CEO at Tag Systems adds: “With this certification, we are excited to support our partners in issuing top-of-wallet biometric cards that utilize Fingerprints and ST latest technologies. Together, we are creating convenient, hygienic, and secure transactions for all purchases.” Following a partnership agreement i
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial7.12.2023 08:00:00 CET | Press release
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decadesMC2-25 CKD uses a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skinMC2-25 CKD has the potential to become the world’s first approved treatment for pre-dialysis Chronic Kidney Disease-associated Pruritus (CKD-aP), a debilitating condition thought to affect a significant proportion of the ~800 million people globally who suffer from Chronic Kidney Disease (CKD)111 patients enrolled in the multi-center trial across Europe with topline results expected in Q2 2024 Copenhagen, December 7th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions,